Literature DB >> 6227281

Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

H L Muytjens, J van der Ros-van de Repe, G van Veldhuizen.   

Abstract

An agar dilution method was used to measure the minimal inhibitory concentrations of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid against 496 clinical isolates. Ciprofloxacin and norfloxacin were active against all species tested (90% minimal inhibitory concentrations less than or equal to 8 micrograms/ml), although ciprofloxacin was somewhat more active, e.g., against gram-positive cocci. Pipemidic acid and nalidixic acid were active against most of the members of the Enterobacteriaceae, but Klebsiella species and Providencia stuartii were only inhibited by a high concentration of nalidixic acid.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6227281      PMCID: PMC185159          DOI: 10.1128/AAC.24.2.302

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Norfloxacin and the antibacterial gamma pyridone beta carboxylic acids.

Authors:  S W Newsom; J Matthews; M Amphlett; R E Warren
Journal:  J Antimicrob Chemother       Date:  1982-07       Impact factor: 5.790

2.  Comparative activities of 13 beta-lactam antibiotics.

Authors:  H L Muytjens; J van der Ros-van de Repe
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191

3.  In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.

Authors:  J Downs; V T Andriole; J L Ryan
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

  3 in total
  48 in total

1.  Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant.

Authors:  Y Inoue; K Sato; T Fujii; K Hirai; M Inoue; S Iyobe; S Mitsuhashi
Journal:  J Bacteriol       Date:  1987-05       Impact factor: 3.490

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.

Authors:  N X Chin; D C Brittain; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

4.  Activity of ofloxacin and pefloxacin against Mycobacterium leprae in mice.

Authors:  S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

5.  Pharmacokinetics of three oral formulations of ciprofloxacin.

Authors:  R L Davis; J R Koup; J Williams-Warren; A Weber; A L Smith
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria.

Authors:  S Saavedra; C H Ramírez-Ronda; M Nevárez
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

7.  Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.

Authors:  H Van Poppel; M Wegge; H Dammekens; V Chysky
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

8.  A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.

Authors:  L Shrire; J Saunders; R Traynor; H J Koornhof
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

10.  Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.

Authors:  M V Borobio; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.